Effect of mTOR inhibitor on autoimmune thyroiditis
Kazan medical journal · 12.03.2026 · 107 (2) · 210-219
DOI: 10.17816/kmj642165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kazan medical journal, online erschienen am 12.03.2026. Verfasst von Anastasia N. Tikhonova und 3 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In autoimmune thyroiditis, hormone replacement therapy generally does not inhibit the activity of autoreactive T lymphocytes destroying the thyroid gland and promoting the antithyroid antibody response at the early stages of the disease. AIM: This work aimed to find an approach aimed at suppressing the autoimmune reaction in autoimmune thyroiditis. METHODS: Experimental autoimmune thyroiditis (EAT) was induced by double (at day 1 and day 14) thyroglobulin immunization of 15 weeks old C57BL/6 mice using complete and incomplete Freund’s adjuvant. Experimental animals were given a 0.05% NaI solution during feeding. The mice were divided into three groups; group 1 included intact mice (n = 5), group 2 included mice with induced EAT (n = 7), and group 3 included mice with induced EAT and subsequently administered sirolimus (n = 7). CD4+, CD8+, double-positive and double-negative T lymphocytes, and CD4+CD25+FoxP3+ T cell levels were determined using flow cytometry. Follicle destruction was measured by hematoxylin and eosin staining and the apoptosis was measured by staining with active caspase-3 antibodies. Thyroid antibodies were determined using enzyme-linked immunosorbent assay. Statistical processing was performed using one-way ANOVA and Student’s t-test (p 0.05); data were presented as mean ± standard deviation (SD). Distribution normality was tested using the Shapiro–Wilk and Bartlett tests. RESULTS: In the EAT group, the mTOR protein inhibitor (sirolimus) prevented thymus involution, increased the number of thymic regulatory T cells, and suppressed the secretion of IFN-γ and IL-17A cytokines. The inhibitor reduced lymphoid infiltration (D450 = 0.25) compared to mice with EAT (D450 = 2.4) and cellular apoptosis (D450 = 0.005 vs 0.0125 in the EAT group). This, in turn, resulted in lower levels of thyroid peroxidase autoantibodies (D450 = 3.0 compared to 19 in the experimental group). Therefore, sirolimus suppresses the autoimmune reaction by activating regulatory T immunity. CONCLUSION: Sirolimus helps reduce the autoimmune aggression, improve the thyroid gland structure, and mitigate the severity of the disease.
Zitieren
APA
Tikhonova, A. N., Burtseva, A. V., Tikhomirova, M. V., & Abramova, Z. I. (2026). Effect of mTOR inhibitor on autoimmune thyroiditis. Kazan medical journal, 107(2), 210-219. https://doi.org/10.17816/kmj642165
Vancouver
Tikhonova AN, Burtseva AV, Tikhomirova MV, Abramova ZI. Effect of mTOR inhibitor on autoimmune thyroiditis. Kazan medical journal. 2026;107(2):210-219. doi:10.17816/kmj642165
BibTeX
@article{Tikhonova2026,
author = {Tikhonova, Anastasia N. and Burtseva, Anastasia V. and Tikhomirova, Maria V. and Abramova, Zinaida I.},
title = {Effect of mTOR inhibitor on autoimmune thyroiditis},
journal = {Kazan medical journal},
year = {2026},
volume = {107},
number = {2},
pages = {210--219},
doi = {10.17816/kmj642165}
}
EUVIMED